KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.

Kubota Pharmaceutical Holdings Co., Ltd.

4596

JP3266500002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 11/06/2024 BST			5-day change	1st Jan Change
70 ^JPY	-1.41%		-2.78%	-12.50%

03-22	Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	MT
03-21	Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	CI

Acucela Inc. Appoints Michael Schutzler to its Board of Directors

June 19, 2012 at 01:00 pm

Acucela Inc. announced that it has appointed Michael Schutzler to its Board of Directors. Mr. Schutzler is currently chief executive officer of Livemocha.

Latest news about Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	03-22	MT
Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	03-21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	10/08/23	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/02/23	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	11/11/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	11/11/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥3.1 million in funding from Barclays Bank PLC, Investment Arm	14/08/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	12/08/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	12/08/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Database Lock for Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease and Expected Release of Top-Line Results in August 2022	27/07/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	13/05/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	14/02/22	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2021	12/11/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Consolidated Financial Results for the Six Months Ended June 30, 2021	12/08/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending Dec. 31, 2021	12/08/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021	13/05/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	12/02/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	12/02/21	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it has received ¥4.59 million in funding from Barclays Bank PLC, Investment Arm	12/07/20	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥4.59 million in funding from Barclays Bank PLC, Investment Arm	25/06/20	CI

Chart Kubota Pharmaceutical Holdings Co., Ltd.

Duration

Period

Chart Kubota Pharmaceutical Holdings Co., Ltd.

More charts

Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.	-12.50%	25.47M
ELI LILLY AND COMPANY	+48.39%	779B
JOHNSON & JOHNSON	-6.13%	354B
MERCK & CO., INC.	+20.61%	333B
ABBVIE INC.	+10.00%	301B
ASTRAZENECA PLC	+16.98%	249B
ROCHE HOLDING AG	-1.76%	216B
NOVARTIS AG	+11.09%	214B
AMGEN INC.	+5.80%	163B
PFIZER, INC.	-2.50%	159B

Other Pharmaceuticals

Kubota Pharmaceutical Holdings Co., Ltd.

Equities

4596

JP3266500002

Pharmaceuticals

Acucela Inc. Appoints Michael Schutzler to its Board of Directors

Latest news about Kubota Pharmaceutical Holdings Co., Ltd.

Chart Kubota Pharmaceutical Holdings Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals